US58933Y1055 - Common Stock - Premarket: 92.52 +0.2 (+0.22%)
We assign a fundamental rating of 5 out of 10 to MRK. MRK was compared to 261 industry peers in the Pharmaceuticals industry. MRK has a medium financial health rating, its profitability is only medium as well. MRK is not valued too expensively and it also shows a decent growth rate.
ROA (12.35%) VS Industry: 94% outperformed.
ROE (34.17%) VS Industry: 79% outperformed.
Profit Margin (26.26%) VS Industry: 94% outperformed.
Price/Earnings (13.19) VS Industry: 62% outperformed.
Price/Book (6.11) VS Industry: 9% outperformed.
Enterprise Value/ EBITDA (10.42) VS Industry: 30% outperformed.
Past | Future | ||||||
---|---|---|---|---|---|---|---|
5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
EPS | 10.62% | 12.99% | 20.07% | 17.47% | 8.42% | 10% | 8.43% |
Revenue | 4.12% | 4.82% | 12.41% | 18.92% | 7.43% | 6.2% | 3.64% |
Debt/Equity (0.8) VS Industry: 13% outperformed.
Quick Ratio (1.02) VS Industry: 16% outperformed.
Current Ratio (1.27) VS Industry: 16% outperformed.
Altman-Z (3.67) VS Industry: 74% outperformed.
Dividend Yield (3.14%) VS Industry: 55% outperformed.
NYSE:MRK (5/16/2022, 7:19:10 PM)+1.91 (+2.11%)
GICS Sector | Health Care | ||
GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
GICS Industry | Pharmaceuticals | ||
Earnings (Last) | 04-28 2022-04-28/bmo | Earnings (Next) | 07-28 2022-07-28 |
Ins Owners | 0.06% | Inst Owners | 72.97% |
Market Cap | 233.46B | Analysts | 77.06 |
PE | 13.19 | Fwd PE | 12.55 |
PEG (NY) | 0.75 | PEG (5Y) | 1.24 |
P/S | 4.33 | P/B | 6.11 |
EV/EBITDA | 10.42 |
ROA | 12.35% | ROE | 34.17% |
PM | 26.26 | Asset Turnover | 0.47 |
EPS 1Y | 20.07% | EPS 3Y | 12.99% |
EPS 5Y | 10.62% | EPS growth Q2Q | 52.86% |
EPS Next Y | 17.47% | EPS Next 2Y | 8.42% |
EPS Next 3Y | 10% | EPS Next 5Y | 8.43% |
Revenue growth 1Y | 12.41% | Revenue growth 3Y | 4.82% |
Revenue growth 5Y | 4.12% | Revenue growth Q2Q | 31.63% |
Revenue Next Year | 18.92% | Revenue Next 2Y | 7.43% |
Revenue Next 3Y | 6.2% | Revenue Next 5Y | 3.64% |
Current Ratio | 1.27 | Quick Ratio | 1.02 |
Altman-Z | 3.67 | F-Score | 3 |
Debt/Equity | 0.8 |
Dividend Yield | 3.14% | Dividend Growth | 9.88% |
DP | 35.03% | Ex-Date | 03-14 2022-03-14 (0.69) |
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA